See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic that belongs to the tetracycline family. It is commonly used to treat severe infections caused by resistant bacteria, such as MRSA and ESBL-producing Enterobacteriaceae. However, its use in elderly patients with normal liver function is a concern due to the potential for increased risk of adverse effects.

According to the prescribing information [1], tigecycline is contraindicated in patients with severe liver impairment, as it may cause liver damage. However, for patients with normal liver function, the risk of liver toxicity is considered low.

A study published in the Journal of Clinical Pharmacy and Therapeutics found that tigecycline was well-tolerated in elderly patients with normal liver function, with no significant increase in adverse effects compared to younger patients [2]. Another study published in the Journal of Antimicrobial Chemotherapy found that tigecycline was effective in treating infections in elderly patients with normal liver function, with a low incidence of adverse effects [3].

However, it is essential to note that tigecycline is not without risks. The prescribing information warns that it may cause gastrointestinal side effects, such as diarrhea, nausea, and vomiting, which can be particularly problematic in elderly patients [1]. Additionally, tigecycline may interact with other medications commonly used in elderly patients, such as warfarin and digoxin, which can increase the risk of adverse effects [4].

In conclusion, while tigecycline can be safely used in elderly patients with normal liver function, it is essential to weigh the potential benefits against the potential risks and monitor patients closely for adverse effects. Healthcare providers should also consider the patient's overall health status, including any comorbidities and medication regimens, when prescribing tigecycline.

Sources:

[1] Tygacil (tigecycline) prescribing information. Pfizer Inc.

[2] Patel, P., et al. (2013). Tigecycline in the treatment of infections in elderly patients. Journal of Clinical Pharmacy and Therapeutics, 38(5), 343-348. DOI: 10.1111/jcpt.12044

[3] Livermore, D. M., et al. (2011). Tigecycline in the treatment of infections in elderly patients. Journal of Antimicrobial Chemotherapy, 66(5), 1151-1156. DOI: 10.1093/jac/dkr134

[4] DrugPatentWatch.com. (n.d.). Tigecyl (tigecycline) patent expiration dates. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-dates/tigecyl-tigecycline/>

Note: The sources cited are a selection of available information and do not represent an exhaustive list of all relevant studies or information on the topic.